Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, Xu M, Matsui H, Tokumitsu Y, Shindo Y, Watanabe Y, Tomochika S, Maeda N, Iida M, Suzuki N, Takeda S, Hazama S, Ioka T, Hoshii Y, Ueno T, Nagano H. Furuya K, et al. Among authors: nakagami y. BMC Cancer. 2024 Feb 2;24(1):165. doi: 10.1186/s12885-024-11924-4. BMC Cancer. 2024. PMID: 38308214 Free PMC article.
Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, Iida M, Tsunedomi R, Takeda S, Yoshino S, Okayama N, Suehiro Y, Yamasaki T, Fujita T, Kawakami Y, Ueno T, Nagano H. Kuwahara T, et al. Among authors: nakagami y. Br J Cancer. 2019 Oct;121(8):659-665. doi: 10.1038/s41416-019-0559-6. Epub 2019 Sep 6. Br J Cancer. 2019. PMID: 31488881 Free PMC article.
Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer.
Yamada K, Hazama S, Suzuki N, Xu M, Nakagami Y, Fujiwara N, Tsunedomi R, Yoshida S, Tomochika S, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Watanabe Y, Iida M, Takeda S, Ioka T, Ueno T, Ogihara H, Hamamoto Y, Hoshii Y, Kawano H, Fujita T, Kawakami Y, Nagano H. Yamada K, et al. Among authors: nakagami y. Oncol Lett. 2021 Jan;21(1):10. doi: 10.3892/ol.2020.12271. Epub 2020 Nov 3. Oncol Lett. 2021. PMID: 33240416 Free PMC article.
CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule.
Nakagami Y, Hazama S, Suzuki N, Yoshida S, Tomochika S, Matsui H, Shindo Y, Tokumitsu Y, Matsukuma S, Watanabe Y, Iida M, Tsunedomi R, Takeda S, Fujita T, Kawakami Y, Ogihara H, Hamamoto Y, Ioka T, Tanabe T, Ueno T, Nagano H. Nakagami Y, et al. BMC Cancer. 2022 Oct 18;22(1):1071. doi: 10.1186/s12885-022-10181-7. BMC Cancer. 2022. PMID: 36253752 Free PMC article.
Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer.
Chidimatsu H, Tsunedomi R, Nakagami Y, Xu M, Nakajima M, Nakashima-Nakasuga C, Tomochika S, Yoshida S, Suzuki N, Watanabe Y, Matsui H, Shindo Y, Tokumitsu Y, Iida M, Takeda S, Ioka T, Ueno T, Tanabe T, Hoshii Y, Hazama S, Nagano H. Chidimatsu H, et al. Among authors: nakagami y. Anticancer Res. 2023 Jan;43(1):105-114. doi: 10.21873/anticanres.16139. Anticancer Res. 2023. PMID: 36585204
Serum LOX-1 is a novel prognostic biomarker of colorectal cancer.
Nakashima-Nakasuga C, Hazama S, Suzuki N, Nakagami Y, Xu M, Yoshida S, Tomochika S, Fujiwara N, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Maeda N, Tsunedomi R, Iida M, Takeda S, Yoshino S, Ueno T, Hamamoto Y, Ogihara H, Hoshii Y, Nagano H. Nakashima-Nakasuga C, et al. Among authors: nakagami y. Int J Clin Oncol. 2020 Jul;25(7):1308-1317. doi: 10.1007/s10147-020-01673-2. Epub 2020 Apr 11. Int J Clin Oncol. 2020. PMID: 32277394
Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials.
Maeda H, Hazama S, Iwamoto S, Oba K, Tsunedomi R, Okayama N, Suehiro Y, Yamasaki T, Nakagami Y, Suzuki N, Nagano H, Sakamoto J, Mishima H, Nagata N. Maeda H, et al. Among authors: nakagami y. Oncol Lett. 2019 Nov;18(5):4555-4562. doi: 10.3892/ol.2019.10787. Epub 2019 Aug 29. Oncol Lett. 2019. PMID: 31611963 Free PMC article.
Correction: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, Iida M, Tsunedomi R, Takeda S, Yoshino S, Okayama N, Suehiro Y, Yamasaki T, Fujita T, Kawakami Y, Ueno T, Nagano H. Kuwahara T, et al. Among authors: nakagami y. Br J Cancer. 2019 Nov;121(11):983-984. doi: 10.1038/s41416-019-0605-4. Br J Cancer. 2019. PMID: 31624318 Free PMC article.
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
Nakajima M, Hazama S, Tamada K, Udaka K, Kouki Y, Uematsu T, Arima H, Saito A, Doi S, Matsui H, Shindo Y, Matsukuma S, Kanekiyo S, Tokumitsu Y, Tomochika S, Iida M, Yoshida S, Nakagami Y, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Nagano H. Nakajima M, et al. Among authors: nakagami y. Cancer Immunol Immunother. 2020 Aug;69(8):1651-1662. doi: 10.1007/s00262-020-02518-7. Epub 2020 Mar 26. Cancer Immunol Immunother. 2020. PMID: 32219501 Free PMC article. Clinical Trial.
200 results